BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$50M+161.9% YoY

Gross Profit

$50M99.5% margin

Operating Income

-$50M-100.1% margin

Net Income

-$74M-148.6% margin

EPS (Diluted)

$-0.40

QoQ Revenue Growth

+5.9%

Cash Flow

Operating Cash Flow

-$78M

Free Cash Flow

-$78M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$528M

Total Liabilities

$692M

Stockholders' Equity

-$164M

Cash & Equivalents

$396M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$50M	$19M	+161.9%
Gross Profit	$50M	$13M	+278.2%
Operating Income	-$50M	-$51M	+2.8%
Net Income	-$74M	-$64M	-15.4%

Revenue Segments

Collaborative and Other Research and Development

$30,000100%

BCRX Q1 2022 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena